Zaleplon

Aka: Zaleplon, Sonata

advertisement

II. Mechanism

  1. Nonbenzodiazepine Hypnotic Agent (Benzodiazepine Receptor Agonist)

III. Indication

  1. Insomnia
  2. Consider for early awakening in middle of night

IV. Pharmacokinetics

  1. Half-Life: 1 hour
  2. Peak Onset: 30 minutes
  3. Duration
    1. Typically 4 hours, but may be as long as 6-8 hour
  4. Metabolized by CYP450 3A4

V. Dosing

  1. Start: 5-10 mg orally at bedtime
  2. Elderly: 5 mg orally at bedtime
  3. Maximum: 20 mg orally at bedtime

VI. Adverse Effects

  1. See Nonbenzodiazepine Hypnotic Agent for common effects
  2. Altered color perception

VII. Advantages

  1. See Nonbenzodiazepine Hypnotic Agent
  2. Effective in middle of night awakening
    1. Can take mid-way through sleep period

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Zaleplon." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies (from Trip Database) Open in New Window

Cost: Medications

zaleplon (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
ZALEPLON 10 MG CAPSULE Generic $0.29 each
ZALEPLON 5 MG CAPSULE Generic $0.24 each
sonata (on 6/1/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
SONATA 10 MG CAPSULE Generic $0.29 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Ontology: zaleplon (C0251504)

Definition (NCI) A nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A receptor, thereby affecting the chloride channel ionophore complex and potentiating the inhibitory effects of GABA. In addition, zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C085665
SnomedCT 321187004, 116104009, 387012004
LNC LP30650-3, MTHU015092
English Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl-, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide, zaleplon, zaleplon (medication), ZALEPLON, zaleplon [Chemical/Ingredient], Zaleplon (product), Zaleplon (substance), Zaleplon
Spanish zaleplón (producto), zaleplón (sustancia), zaleplón
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Sonata (C0876170)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C085665
English Sonata, sonata, Lundbeck brand of zaleplon, Wyeth brand of zaleplon, Zelepion, AHP brand of zaleplon
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2019 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo